Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Angiodynamics (ANGO) Operating Expenses (2016 - 2025)

Angiodynamics (ANGO) has disclosed Operating Expenses for 16 consecutive years, with $50.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses changed 0.18% year-over-year to $50.9 million, compared with a TTM value of $200.3 million through Nov 2025, down 49.46%, and an annual FY2025 reading of $197.7 million, down 50.79% over the prior year.
  • Operating Expenses was $50.9 million for Q4 2025 at Angiodynamics, down from $52.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $242.4 million in Q1 2024 and bottomed at $42.3 million in Q1 2021.
  • Average Operating Expenses over 5 years is $61.4 million, with a median of $51.8 million recorded in 2024.
  • The sharpest move saw Operating Expenses soared 390.4% in 2024, then plummeted 79.86% in 2025.
  • Year by year, Operating Expenses stood at $49.2 million in 2021, then grew by 8.04% to $53.2 million in 2022, then rose by 0.36% to $53.4 million in 2023, then fell by 4.46% to $51.0 million in 2024, then dropped by 0.18% to $50.9 million in 2025.
  • Business Quant data shows Operating Expenses for ANGO at $50.9 million in Q4 2025, $52.5 million in Q3 2025, and $48.0 million in Q2 2025.